Features of asthma which provide meaningful insights for understanding the disease heterogeneity.

Authors:
Deliu M; Yavuz TS; Sperrin M; Belgrave D; Sahiner UM and 3 more

Journal:
Clin Exp Allergy

Publication Year: 2017

DOI:
10.1111/cea.13014

PMCID:
PMC5763358

PMID:
28833810

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Exp Allergy

Abbreviation: Clin Exp Allergy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anaphylaxis in Brazil between 2011 and 2019.
Tanno LK; Molinari N; Annesi-Maesano I and 2 more (2022) - Transparency Score: 3/6
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with na…
Eide JG; Wu J; Stevens WW and 16 more (2022) - Transparency Score: 3/6
Association between allergic sensitization and intestinal parasite infection in schoolchildren in G…
Brandt O; Wegenstein B; Müller I and 12 more (2022) - Transparency Score: 3/6
Burden of allergic disease among ethnic minority groups in high-income countries.
Jones CJ; Paudyal P; West RM and 5 more (2022) - Transparency Score: 2/6
Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctiv…
de Blay F; Gherasim A; Domis N and 2 more (2022) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Prof. Custovic reports personal fees from Novartis, personal fees from Regeneron/Sanofi, personal fees from ALK, personal fees from Bayer, personal fees from ThermoFisher, personal fees from GlaxoSmithKline, personal fees from Boehringer Ingelheim, outside the submitted work."

Evidence found in paper:

"Funding information"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025